Verastem Reports Strong Preliminary Data for KRAS G12D Inhibitor VS-7375, Plans Phase 3 Trials
VSTM is trading near its 52-week low of $3.55 (14% above the low).
Summary
Verastem announced compelling preliminary clinical data for its KRAS G12D inhibitor, VS-7375, showing strong anti-tumor activity and a favorable safety profile in advanced solid tumors, alongside a clear development roadmap towards Phase 3 trials.
Key Events · Product Development and Regulatory · VSTM
-
Strong Preliminary Efficacy for VS-7375
93% (13/14) of heavily pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC) patients receiving 900 mg QD monotherapy achieved greater than 50% reduction in the tumor marker CA19-9.
-
Favorable Safety Profile
VS-7375 demonstrated a favorable safety profile across monotherapy and combination cohorts, with primarily low-grade, manageable gastrointestinal adverse events and no clinically significant cumulative toxicities.
-
Broad Anti-Tumor Activity
Clinical activity was observed at multiple dose levels across metastatic pancreatic, colorectal, and advanced non-small cell lung cancers, both as monotherapy and in combination with anti-EGFR therapy.
-
Strategic Collaboration Intent
Verastem announced its intent to enter into an agreement with Erasca, Inc. to evaluate VS-7375 in combination with ERAS-0015 for KRAS G12D mutant solid tumors, with potential for future clinical trials.
Analysis · VSTM · Life Sciences
This 8-K details highly positive preliminary clinical data for Verastem's investigational KRAS G12D inhibitor, VS-7375, across multiple advanced solid tumors including pancreatic, colorectal, and lung cancers. The strong efficacy signals, particularly the 93% CA19-9 reduction in heavily pretreated pancreatic cancer patients, coupled with a favorable safety profile, are critical for the company, especially given its previously disclosed "going concern" doubt. The outlined development roadmap, including planned Phase 3 trials and a potential collaboration with Erasca, Inc., provides a clear path forward and could significantly enhance investor confidence and address long-term viability concerns.
At the time of this filing, VSTM was trading at $4.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $369.9M. The 52-week trading range was $3.55 to $11.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.